Catalent, a drug delivery technology specialist, has appointed Kevin Hambly as Vice President, Business Development and Licensing for Catalent Biologics.
Hambly will be responsible for leading business development activities around Catalent’s proprietary SMARTag bioconjugation platform, as well as further developing and commercialising Catalent Biologics’ portfolio of proprietary technologies.
Hambly joins Catalent Biologics after spending nine years at Seattle Genetics, where he was most recently Director of Business Development and responsible for leading out-licensing activities for the company’s Antibody Drug Conjugate (ADC) technology.
Catalent’s SMARTag site-specific protein-modification and linker technologies were developed by Redwood Bioscience to enable the generation of homogenous bioconjugates (including ADCs and other protein conjugates) engineered to enhance potency, safety and stability. Catalent acquired Redwood Bioscience in 2014.
